U.S. Acellular Dermal Matrices Market Size to Exceed USD 7.14 Bn by 2032

The U.S. Acellular Dermal Matrices Market, estimated at USD 3.44 Bn in 2025, is expected to exhibit a CAGR of 11% and reach USD 7.14 Bn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Increasing product approval by the regulatory bodies is expected to drive the growth of the U.S. acellular dermal matrices market over the forecast period. For instance, in January 2021, Medskin Suwelack, a provider of medical care products, announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance to Medskin Suwelack’s MatriDerm product portfolio. MatriDerm is a single-use 3D acellular dermal matrix used to manage full thickness and partial wounds.

U.S. Acellular Dermal Matrices Market - Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spreads quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems regarding the transportation of products from one place to another.

COVID-19 had a positive impact on the U.S. acellular dermal matrices market. During the start of July 2020, a few cases were reported of severe fungal infections with COVID-19 at the same time. According to the Union Health Ministry during the first wave of COVID-19, India contributed approximately 71% of the global cases of mucormycosis in patients with COVID-19. Thus, rise in the cases of mucormycosis infectious disease increased the usage of anti-fungal drugs.

U.S. Acellular Dermal Matrices Market: Key Developments

On May 25, 2023, AlloSource, one of the largest nonprofit allograft providers in the U.S. creating innovative cellular and tissue products to help surgeons heal their patients, announced the launch of AlloMend Duo Acellular Dermal Matrix (ADM), a natural solution for soft tissue reconstruction.

In December 2021, Paragon 28, Inc., a company which designs, develops, distributes, and sells foot and ankle surgical systems, launched its ParaDerm NF Dermal Matrix, providing surgeons a structural allograft for applications beneath the skin in cases where additional structural value is desired. ParaDerm has a rich clinical history (over ten years of implantation) and is produced using a highly technical process that reduces nucleic acids and other antigenic materials while preserving the collagen matrix. This extracellular matrix promotes cellular infiltration, attachment, and cell proliferation at each stage of the healing process.1 This biologic process is crucial to the integration and remodeling of the allograft by host cells.

 

Browse 36 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on “Global U.S. Acellular Dermal Matrices Market”- Forecast to 2030, Global U.S. Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, Infections), Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others), and By Place of Setting (Hospitals, Ambulatory Surgical Centers, and Office Based).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-acellular-dermal-matrices-market-4442

Key Takeaways of the Global U.S. Acellular Dermal Matrices Market:

• The U.S. acellular dermal matrices market is expected to exhibit a CAGR of 11% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the U.S. acellular dermal matrices market.
• Among origin, the human dermis segment is expected to hold a dominant position in the U.S. acellular dermal matrices market during the forecast period. This is due to the high preference for human-based products among patients and surgeons in the region. Human dermis provides several advantages over animal-derived tissues including lower risk of infection transmission and higher biocompatibility. According to the American Society of Plastic Surgeons (ASPS), approximately 93% of plastic surgeons use human-based acelluar dermal matrices in procedures. The established safety and efficacy profile of human dermis leads to its adoption as the standard of care for procedures like breast reconstruction post-mastectomy.
• Among application, chronic wound is expected to held second dominant position in the U.S. acellular dermal matrices market, owing to the increasing research and development activities by the key market players. For instance, in August 2022, PolyNovo Biomaterials Pty Ltd., a company that develops a range of biocompatible and biodegradable polymers for use in medical devices, transdermal drugs and others, initiated a clinical trial titled “A Prospective, Multicenter, Open Label, Randomized, Controlled Clinical Study Evaluating the Effect of NovoSorb SynPath Dermal Matrix Compared to Standard of Care (SOC) In the Treatment of Nonresponsive, Chronic Diabetic Foot Ulcers”. The study is estimated to get completed by March 1, 2024. It will evaluate the efficacy of SynPath, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment.
• The major players operating in the U.S. acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, and AlloSource